Literature DB >> 29607152

Wet M1a non-small cell lung cancer: is it possible to predict recurrence of pleural effusion?

Fernando Conrado Abrao1, Igor Renato Louro Bruno de Abreu1, Geisa Garcia Viana2, Mariana Campello de Oliveira2, Elnara Marcia Negri1, Riad Naim Younes1.   

Abstract

BACKGROUND: The propose was to recognize risk factors of malignant pleural effusion (MPE) recurrence in patients with symptomatic M1a non-small cell lung cancer (NSCLC).
METHODS: All patients with NSCLC and MPE submitted to pleural palliative procedures were enrolled in a prospective study. Group I contained patients who had pleural recurrence, and Group II with no pleural recurrence. Prognostic factors for pleural recurrence were identified by univariable analysis, using Fisher's exact test for categorical variables and Student's t test for quantitative variables. Afterwards the significant variables were entered into a multivariable logistic regression analysis (with P<0.05 considered significant). Receiver operating characteristics (ROC) analysis determined the cutoff points for continuous variables.
RESULTS: A total of 82 patients were included in the analysis. There were 15 patients (18.3%) in Group I and 67 patients (81.7%) in Group II. Univariable analysis regarding factors affecting postoperative recurrence was: adenosine deaminase concentration in pleural fluid <16 mg/dL (P=0.04), albumin concentration in pleural fluid <2.4 mg/dL (P=0.03), administration of second-line palliative chemotherapy (P=0.018) and type of procedure [therapeutic pleural aspiration (TPA)] (P=0.023). At the multivariable analysis, only the type of procedure (TPA) (P=0.031) was identified as independent predictor of recurrence.
CONCLUSIONS: The identification of this factor may assist the choice of the optimal palliative technique; at the first episode of MPE in NSCLC patients and definitive procedure as pleurodesis or indwelling pleural catheter are recommended.

Entities:  

Keywords:  Recurrence; lung neoplasms; palliative care

Year:  2018        PMID: 29607152      PMCID: PMC5864605          DOI: 10.21037/jtd.2018.01.53

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  34 in total

1.  Management of malignant pleural effusions.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-11       Impact factor: 21.405

2.  Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial.

Authors:  Helen E Davies; Eleanor K Mishra; Brennan C Kahan; John M Wrightson; Andrew E Stanton; Anur Guhan; Christopher W H Davies; Jamal Grayez; Richard Harrison; Anjani Prasad; Nicola Crosthwaite; Y C Gary Lee; Robert J O Davies; Robert F Miller; Najib M Rahman
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

3.  Pleural fluid glucose: A predictor of unsuccessful pleurodesis in a preselected cohort of patients with malignant pleural effusion.

Authors:  Ioannis Pantazopoulos; Theodoros Xanthos; Ioannis Vlachos; Zacharias Kakoulas; Konstantinos Stroumpoulis; Athanasios Chalkias; Georgios Tsoukalas; Antonia Koutsoukou
Journal:  J BUON       Date:  2014 Oct-Dec       Impact factor: 2.533

4.  Asymptomatic hydropneumothorax after therapeutic thoracentesis for malignant pleural effusions.

Authors:  G W Boland; G S Gazelle; M J Girard; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  1998-04       Impact factor: 3.959

5.  Treatment of malignant pleural effusion with drainage, with and without instillation of talc.

Authors:  P G Sørensen; T L Svendsen; B Enk
Journal:  Eur J Respir Dis       Date:  1984-02

Review 6.  Malignant pleural effusion and algorithm management.

Authors:  Konstantinos Zarogoulidis; Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Nikolaos Machairiotis; Ioanna Kougioumtzi; Nikolaos Courcoutsakis; Eirini Terzi; Bojan Zaric; Haidong Huang; Lutz Freitag; Dionysios Spyratos
Journal:  J Thorac Dis       Date:  2013-09       Impact factor: 2.895

7.  Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.

Authors:  Jian-Bo Lin; Fan-Cai Lai; Xu Li; Yuan-Rong Tu; Min Lin; Min-Lian Qiu; Rong-Gang Luo; Bo Liu; Jing-Wei Lin
Journal:  J Drug Target       Date:  2016-06-29       Impact factor: 5.121

8.  Prognostic value of pleural effusion in patients with non-small cell lung cancer.

Authors:  S Sugiura; Y Ando; H Minami; M Ando; S Sakai; K Shimokata
Journal:  Clin Cancer Res       Date:  1997-01       Impact factor: 12.531

9.  Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion: The TIME1 Randomized Clinical Trial.

Authors:  Najib M Rahman; Justin Pepperell; Sunita Rehal; Tarek Saba; Augustine Tang; Nabeel Ali; Alex West; Gihan Hettiarachchi; Dipak Mukherjee; Johnson Samuel; Andrew Bentley; Lee Dowson; Jonathan Miles; C Frank Ryan; Ken Y Yoneda; Anoop Chauhan; John P Corcoran; Ioannis Psallidas; John M Wrightson; Rob Hallifax; Helen E Davies; Y C Gary Lee; Melissa Dobson; Emma L Hedley; Douglas Seaton; Nicky Russell; Margaret Chapman; Bethan M McFadyen; Rachel A Shaw; Robert J O Davies; Nick A Maskell; Andrew J Nunn; Robert F Miller
Journal:  JAMA       Date:  2015 Dec 22-29       Impact factor: 56.272

10.  Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis.

Authors:  Huan Xia; Xiao-Juan Wang; Qiong Zhou; Huan-Zhong Shi; Zhao-Hui Tong
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  1 in total

1.  Prognostic factors of recurrence of malignant pleural effusion: what is the role of neoplasia progression?

Authors:  Fernando Conrado Abrão; Igor Renato Louro B de Abreu; Mariana Campello de Oliveira; Geisa Garcia Viana; José Franklin Soares Pompa Filho; Riad Naim Younes; Elnara Marcia Negri
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.